Note: This document has been translated from the Japanese original for reference purposes only. In the event of any discrepancy between this translated document and the Japanese original, the original shall prevail. October 30, 2026 Consolidated…
Note: This document has been translated from the Japanese original for reference purposes only. In the event of
any discrepancy between this translated document and the Japanese original, the original shall prevail.
October 30, 2026
Consolidated Financial Results for the Six Months Ended September 30, 2026
(Under Japanese GAAP)
Company name: Japan Lifeline Co., Ltd.
Listing:
Tokyo Stock Exchange
Securities code:
7575
URL:
https://www.japanlifeline.com/
Representative:
Keisuke Suzuki, President and Chief Executive Officer
Inquiries:
Takeyoshi Egawa, Director, and Chief Financial Officer
Telephone:
+81-3-6711-5200
Scheduled date to file semi-annual securities report:
November 13, 2026
Scheduled date to commence dividend payments:
December 15, 2026
Preparation of supplementary material on financial results:
Yes
Holding of financial results briefing:
Yes (for institutional investors and analysts)
(Yen amounts are rounded down to millions, unless otherwise noted.)
- Consolidated financial results for the six months ended September 30, 2026 (April 1, 2026–September 30, 2026)
(Percentages indicate year-on-year changes.)
(1) Consolidated operating results (cumulative)
Net sales
Operating profit
Millions of yen
Six months ended
September 30, 2026
31,353
September 30, 2025
29,285
Note:
Comprehensive income
%
%
Millions of yen
%
Diluted earnings
per share
Yen
Yen
63.15
68.08
–
68.08
(2) Consolidated financial position
Total assets
Millions of yen
7.1
5,468
(17.4)
6,040
(8.8)
4.6
6,620
5.7
6,624
7.4
Six months ended September 30, 2026: ¥4,254 million [(8.8)%]
Six months ended September 30, 2025: ¥4,667 million [(0.3)%]
Basic earnings
per share
Six months ended
September 30, 2026
September 30, 2025
Millions of yen
Net income attributable
to owners of the parent
Ordinary profit
Total net assets
Equity ratio
Millions of yen
Millions of yen
As of
September 30, 2026
80,005
66,414
March 31, 2026
80,211
65,897
Reference:
Equity (Shareholders’ equity + Accumulated other comprehensive income)
As of September 30, 2026:
¥66,332 million
As of March 31, 2026:
¥65,850 million
%
82.9
82.1
4,430
4,774
%
(7.2)
7.7
- Dividends
Annual dividends per share
Q1-end
Q2-end
Yen
Q3-end
Yen
Year-end
Yen
Fiscal year ended
–
0.00
–
March 31, 2026
Fiscal year ending
–
25.00
March 31, 2027
Fiscal year ending
March 31, 2027
–
(forecast)
Notes: 1. Revisions to the most recently announced dividends forecast: None
2. Breakdown of Q2-end dividend for the fiscal year ending March 31, 2027
Ordinary dividend: ¥0.00;
commemorative dividend: ¥25.00
Breakdown of year-end dividend for the fiscal year ending March 31, 2027 (forecast):
Ordinary dividend: ¥56.00; commemorative dividend: ¥0.00
Total
Yen
Yen
54.00
54.00
56.00
81.00
- Consolidated earnings forecast for the fiscal year ending March 31, 2027 (April 1, 2026–March 31, 2027)
(Percentages indicate year-on-year changes.)
Net sales
Millions of yen
Operating profit
% Millions of yen
Net income attributable
to owners of the parent
Ordinary profit
Basic earnings
per share
% Millions of yen
%
Millions of yen
%
Yen
Full year
63,200
6.8
10,700 (15.1)
10,800
Note: Revisions to the most recently announced earnings forecast: None
(14.2)
8,000
(14.4)
114.02
(1) Changes in significant subsidiaries (changes in specified subsidiaries resulting in changes in the scope of consolidation) during
the period: Yes
Newly included: 1 (JLL Med USA Inc.)
Excluded: None
(2) Application of accounting treatments specific to the preparation of semi-annual consolidated financial statements: None
(3) Changes in accounting policies, changes in accounting estimates, and restatement
(i)
Changes in accounting policies due to revisions to accounting standards and other pronouncements: None
(ii)
Changes in accounting policies due to reasons other than (i): None
(iii)
Changes in accounting estimates: None
(iv)
Restatement: None
(4) Number of shares issued (common stock)
(i)
Total number of shares issued at the end of the period (including treasury stock)
As of September 30, 2026
71,300,000 shares
As of March 31, 2026
71,300,000 shares
(ii)
Number of shares of treasury stock at the end of the period
As of September 30, 2026
1,134,058 shares
As of March 31, 2026
1,145,522 shares
(iii)
Average number of shares outstanding during the period
Six months ended September 30, 2026
70,160,889 shares
Six months ended September 30, 2025
70,129,451 shares
Note: The Company has adopted a Board Incentive Plan (BIP) trust, and the Company’s shares held by the trust are
included in the treasury stock deducted in the calculation of the number of shares of treasury stock at the end of the
period and the average number of shares outstanding during the period.
Semi-annual financial results reports are exempt from review conducted by certified public accountants or an audit firm.
Proper use of earnings forecast, and other special matters
The forward-looking statements including earnings forecasts contained in this document are based on information currently
available to the Company and certain assumptions that are deemed to be reasonable. Accordingly, the Company does not
guarantee the achievement of the forecast, and actual results may differ significantly from the forecast due to various factors. For
the assumptions for earnings forecasts and cautions concerning the use thereof, please refer to “1. Overview of Financial
Performance, (3) Consolidated financial guidance” on page 7 of the attached materials.
Contents of Attached Materials
- Overview of Financial Performance .....................................................................................................................................
(1) Operating results .............................................................................................................................................................
2
2
(2) Financial position............................................................................................................................................................
(3) Consolidated financial guidance .....................................................................................................................................
6
7
- Interim Consolidated Financial Statements and Major Notes ..............................................................................................
(1) Interim consolidated balance sheets ................................................................................................................................
8
8
(2) Interim consolidated statements of income and interim consolidated statements of comprehensive income..................
(3) Interim consolidated statements of cash flows ................................................................................................................
9
10
(4) Notes to interim consolidated financial statements .........................................................................................................
Going concern assumption ...........................................................................................................................................
11
11
Significant changes in shareholders’ equity .................................................................................................................
Changes in scope of consolidation or application of equity method .............................................................................
11
11
Interim consolidated statements of cash flows ..............................................................................................................
Segment information, etc. .............................................................................................................................................
11
11
Significant subsequent events .......................................................................................................................................
3. Other.....................................................................................................................................................................................
11
12
Status of production, orders received and sales ....................................................................................................................
12
-1-
- Overview of Financial Performance
(1) Operating results
Forward-looking statements below are based on our judgment as of September 30, 2026.
Business environment
Japan Lifeline is engaged mainly in the manufacture and sale of highly controlled medical devices, primarily focusing on
cardiac devices, for general hospitals in Japan.
The business environment surrounding Japan’s medical devices industry is characterized by the three main dynamics of 1)
expanding structural demand driven by increase in the elderly population, 2) strained medical care delivery system, and 3)
changes in the macroeconomy such as weak yen and inflation, and they are having an increasingly significant impact on the
performance of individual companies. In this environment, medical trends in the market have been constantly changing and the
demand for efficient and relevant solutions to various challenges faced by medical professionals have been increasing more
than ever.
First, on the demand side, the market continues to expand against the backdrop of the increase in the elderly population. In
particular, the number of atrial fibrillation cases in the cardiovascular field has continued to increase at a strong pace since the
mid-2010s. Further, with the number of people aged 75 and older increasing significantly in the years ahead, the shift from
surgeries to less physically taxing endovascular therapy (minimally invasive treatment) is also expected to gather pace. As
minimally invasive treatment will gradually lower the age of eligible patients, it will lead to expansion of the medical device
market, and provide a tailwind for the industry. We expect such structural expansion in demand to form a base that supports
market growth in the future.
Secondly, chronic shortage of resources at medical institutions, which are on the supply side of medical care, has become a
serious issue. Given the shortened working hours and staff shortage following workstyle reform of doctors, there is strong
demand for medical devices that support streamlining of medical care including simplification of procedures and shortening of
treatment time in a clinical environment. This is not just about the pursuit of therapeutic effects but signals that we are now
moving into an era where products that succeed will be the ones contributing toward sustaining the medical care delivery
system.
Thirdly, in terms of macroeconomy, the weakening of the yen and the worldwide inflation could also have an impact on our
profit structure. Even as manufacturing expenses including raw material costs, logistics costs, and labor costs as well as selling,
general and administrative expenses are increasing, it is difficult for us to pass on the rise in such costs immediately to the
selling prices as the official prices of medical devices are set by the government under Japan’s universal healthcare system. For
that reason, we need to continuously monitor inflation as a risk that could put pressure on our profits.
In light of the above recognition of the environment, our important management challenges include diversifying domestic risk
by expanding the business globally and implementing appropriate growth strategies to address the changes in the medical care
trends. As for globalization, our urgent tasks are optimizing domestic products for the overseas market and establishing global
quality standards. In terms of addressing the changes in the medical care trends, R&D related to pulsed field ablation (PFA) for
arrhythmia treatment and the acquisition of pipeline assets such as stent graft and transcatheter aortic valve implantation
(TAVI) for endovascular therapy are examples of our efforts to capture the opportunity. We aim to achieve both sustainable
growth and profitability in this rapidly changing business environment through early incorporation of market needs into our
product lineup, leveraging the unique hybrid business model combining our dual roles of manufacturer and distributor.
-2-
Status of business
For the six months ended September 30, 2026, we saw varied year-over-year performance across key financial metrics. Net
sales grew by 7.1% and gross profit rose by 2.6%. Operating profit declined by 17.4%, while net income attributable to owners
of the parent decreased by 7.2%. In the fourth year of the medium-term management plan (a five-year period from the fiscal
year ended March 31, 2024 to the fiscal year ending March 31, 2028), we continued to work on the following five key
initiatives of “Continuous Introduction of Competitive Products,” “Expansion into New Therapeutic Areas,” “Expansion of
Global Sales,” “Promotion of the OEM Business,” and “Strengthening Management with a Focus on Capital Efficiency.”
Meanwhile, as part of our investments for future growth, we accelerated R&D activities related to the development of new
products and the global optimization of our proprietary products, resulting in higher selling, general and administrative
expenses. As a result, for the six months ended September 30, 2026, net sales increased while operating profit declined.
In terms of sales, both our existing business areas (EP/Ablation and Cardiovascular) and new business areas (Neurovascular
and Gastrointestinal) grew. Despite the revision to reimbursement prices implemented in June 2026, net sales reached a record
high for a six-month period. Net sales from EP/Ablation and Cardiovascular, which are positioned as core businesses within
our existing business areas, increased by 10.3% and 4.1% year on year, respectively. Our new business areas also saw sales
increase by 42.9% in Neurovascular and 34.4%* in Gastrointestinal, sustaining double-digit growth. Cardiac Rhythm
Management, positioned as a stable business, posted a 7.0% decrease in sales.
Selling, general and administrative (SG&A) expenses increased by 1,613 million yen year-over-year, primarily due to R&D
activities and higher personnel expenses, as well as increased outsourcing and other expenses related to a corporate acquisition.
The increase also reflected the non-recurrence of a reversal of allowance for doubtful accounts that had been recognized in the
same period of the previous fiscal year and recorded as a reduction in SG&A expenses. This resulted in a year-over-year
decrease of 1,151 million yen in operating profit, with the operating margin of 17.4%.
Volatility in foreign currency exchange rates had a minimal short-term impact on procurement as our purchases of products
from third parties made in yen accounted for approximately 70% of all transactions and we use the moving average method for
cost of sales. However, the depreciation of the yen against the ringgit increased the cost ratio at our production site in Malaysia
due to the translation of manufacturing expenses denominated in local currency.
Furthermore, we have mitigated supply risks associated with the deteriorating situation in the Middle East by securing raw
materials in advance. As a result, there has been no material impact on product supply to date.
*
Sales of Gastrointestinal included those from the terminated coronary intervention business; without this business, sales would have
increased 41.6% year-over-year.
Business Performance
The earnings for the six months ended September 30, 2026 were as follows:
(Millions of yen, unless otherwise noted)
Six months ended
September 30, 2025
Six months ended
September 30, 2026
% of net sales
YoY
increase/
(decrease)
YoY %
increase/
(decrease)
Product Category
Amount
(i)
% of net sales
Amount
Net sales
29,285
100.0
31,353
100.0
2,068
7.1
(ii) Gross profit
17,557
60.0
18,018
57.5
461
2.6
(iii) Operating profit
6,620
22.6
5,468
17.4
(1,151)
(17.4)
(iv) Ordinary profit
6,624
22.6
6,040
19.3
(584)
(8.8)
(v) Net income attributable to
owners of the parent
4,774
16.3
4,430
14.1
(344)
(7.2)
(i) Net sales
Net sales were 31,353 million yen, an increase of 7.1% year-over-year. For more details, please refer to the “Sales by product”
section later in this report.
(ii) Gross profit
Gross profit was 18,018 million yen, up 2.6% year-over-year. Lower selling prices due to new product promotions, revisions
to reimbursement prices, and other factors, as well as higher manufacturing costs driven in part by soaring raw material costs,
had an impact. However, increased sales volume more than compensated for this impact, resulting in higher gross profit.
-3-
The gross margin was 57.5%, a decrease of 250 bps year-over-year, due to the impact of selling prices noted above.
Meanwhile, the proprietary product sales ratio increased by 210 bps year-over-year to 57.2%, reflecting increased sales of
radiofrequency transseptal wires, intracardiac defibrillation catheter, and other products.
(iii) Operating profit
We reported operating profit of 5,468 million yen, a decrease of 17.4% year-over-year, and operating margin of 17.4% (a
decrease of 520 bps year-over-year). Selling, general and administrative expenses were 12,550 million yen, an increase of
14.8% year-over-year. The main reasons for the increase are as follows:
• An increase in research and development expenses related to the development of PFA systems and other projects
• Higher personnel expenses from salary increases
• An increase in outsourcing expenses related to a corporate acquisition
• The absence of a reversal of allowance for doubtful accounts that had been recognized in the same period of the previous
fiscal year and recorded as a reduction in SG&A expenses
(iv) Ordinary profit
Ordinary profit was 6,040 million yen, down 8.8% year-over-year. Non-operating income totaled 681 million yen, including
gain on valuation of investment securities and reversal of allowance for doubtful accounts. In addition, non-operating expenses
of 109 million yen were recognized, mainly consisting of foreign exchange losses.
(v) Net income attributable to owners of the parent
Net income attributable to owners of the parent was 4,430 million yen, marking a 7.2% decrease year-over-year. Extraordinary
income included a gain on sale of investment securities of 346 million yen.
The income tax burden was 30.1%, up 260 bps.
Sales by product
Product Category
(Millions of yen, unless otherwise noted)
YoY
YoY %
Six months ended
increase/
increase/
September 30, 2026
(decrease)
(decrease)
Six months ended
September 30, 2025
Cardiac Rhythm Management
6,666
6,198
(467)
(7.0)
EP/Ablation
14,707
16,222
1,515
10.3
Cardiovascular
5,936
6,177
240
4.1
Neurovascular
1,187
1,696
509
42.9
Gastrointestinal
787
1,057
270
34.4
29,285
31,353
2,068
7.1
Total
*Note: The main products classified in each product category are as follows.
Cardiac Rhythm
Management
Pacemaker, T-ICD (Transvenous Implantable Cardioverter Defibrillator), S-ICD (Subcutaneous
Implantable Cardioverter Defibrillator), CRT-P (Cardiac Resynchronization Therapy Pacemaker),
CRT-D (Cardiac Resynchronization Therapy Defibrillator), AED (Automated External Defibrillator),
lead management device
EP/Ablation
Electrophysiology catheter, ablation catheter, intracardiac defibrillation catheter, esophageal
temperature monitoring catheter, steerable sheath, hemostatic device for femoral vein, radiofrequency
transseptal wire
Cardiovascular
Vascular graft, Frozen Elephant Trunk, stent graft, atrial septum defect closure device
Neurovascular
Embolic coil, aspiration catheter, microcatheter, stent retriever
Gastrointestinal
Bile-duct tube stent, biliary dilation balloon, contrast catheter, double-lumen dilator, ERCP guide
wire, colonic stent, gastro duodenal stent, Radiofrequency ablation system for oncology
-4-
(i)
Cardiac Rhythm Management
Net sales in Cardiac Rhythm Management reached 6,198 million yen, a decrease of 7.0% year-over-year. Pacemaker sales
were sluggish as competitors’ leadless pacemakers achieved greater market penetration. Net sales of the core product S-ICD
have softened since the second quarter in the current fiscal year as competitors’ newly launched products gained traction in
new implant cases.
(ii) EP/Ablation
Net sales in EP/Ablation reached 16,222 million yen, an increase of 10.3% year-over-year. Sales of core product groups
spearheaded overall sales growth, driven by an approximately 10% year-over-year rise in atrial fibrillation ablation procedures.
By product category, intracardiac defibrillation catheters recorded growth, while net sales of hemostatic devices for femoral
vein also remained strong thanks to an increase in the number of facilities adopting the product as well as an expanded product
lineup. Further, radiofrequency transseptal wires, a proprietary product launched in March 2026, gained market share at a
faster-than-expected pace.
(iii) Cardiovascular
Net sales in Cardiovascular reached 6,177 million yen, an increase of 4.1% year-over-year. The core product Frozen Elephant
Trunk maintained its high market share in a stable market. Sales of abdominal stent graft also grew as enhanced sales measures
proved effective.
(iv) Neurovascular
Net sales in Neurovascular reached 1,696 million yen, an increase of 42.9% year-over-year. Embolic coil sales remained
strong, supported by solid demand for existing models, as well as the launch of new vascular embolization models beginning in
the second quarter of the current fiscal year. Aspiration catheters continued to record double-digit growth, driven by a
significant increase in sales volume, despite an approximately 10% decline in selling prices following the revision to
reimbursement prices. Stent retrievers contributed to revenue increase as sales of the upgraded model expanded largely in line
with the plan.
(v) Gastrointestinal
Net sales in Gastrointestinal amounted to 1,057 million yen, an increase of 34.4% year-over-year. Excluding the coronary
intervention business, which was terminated in the fiscal year ended March 31, 2024, adjusted net sales increased 41.6%. The
mainstay bile-duct tube stent generated significant revenue growth as sales, led by the new model, progressed ahead of plan,
while supply shortages of competitors’ products also contributed. Other products such as biliary dilation balloons and ERCP
guide wires also performed well overall.
-5-
(2) Financial position
Analysis of the interim consolidated balance sheets
(i) Assets
The balance of current assets as of September 30, 2026 was 49,802 million yen, an increase of 755 million yen from the end
of the previous fiscal year. This was mainly due to increases of 1,113 million yen in notes and accounts receivable - trade
and 457 million yen in inventories, partially offset by a decrease of 783 million yen in cash and deposits, resulting from
payments for dividends and income taxes.
The balance of fixed assets was 30,203 million yen, a decrease of 961 million yen from the end of the previous fiscal year.
This was mainly due to decreases of 1,157 million yen in long-term loans receivable, 618 million yen in investment
securities, and 657 million yen in accrued interest in “Other” under investments and other assets, partially offset by an
increase of 1,701 million yen in buildings and structures.
As a result, the balance of total assets was 80,005 million yen, a decrease of 205 million yen from the end of the previous
fiscal year.
(ii) Liabilities
The balance of current liabilities as of September 30, 2026 was 12,829 million yen, a decrease of 768 million yen from the
end of the previous fiscal year. This was primarily due to decreases of 405 million yen in notes and accounts payable - trade
and 243 million yen in accrued expenses included in “Other.”
The balance of long-term liabilities was 762 million yen, an increase of 45 million yen from the end of the previous fiscal
year. This was mainly due to an increase of 74 million yen in asset retirement obligations included in “Other,” partially offset
by a decrease of 28 million yen in lease liabilities included in “Other.”
As a result, the balance of total liabilities was 13,591 million yen, a decrease of 722 million yen from the end of the previous
fiscal year.
(iii) Net assets
The balance of net assets as of September 30, 2026 was 66,414 million yen, an increase of 516 million yen from the end of
the previous fiscal year. This was mainly due to the recording of net income attributable to owners of the parent of 4,430
million yen, partially offset by dividend payments of 3,792 million yen.
Analysis of the interim consolidated statements of cash flows
The balance of cash and cash equivalents as of September 30, 2026 amounted to 11,711 million yen, a decrease of 782
million yen from the end of the previous fiscal year. Cash flows for the first six months of the fiscal year ending March 31,
2027 by activities were as follows.
(i) Cash flows from operating activities
Net cash provided by operating activities was 3,274 million yen (for the first six months of the previous fiscal year, net cash
provided by operating activities was 3,495 million yen). The main factors are profit before income taxes of 6,338 million
yen, despite an increase in trade notes and accounts receivable of 1,111 million yen, an increase in inventories of 456 million
yen, and income taxes paid of 1,676 million yen, which decreased cash flows.
(ii) Cash flows from investing activities
Net cash used in investing activities was 242 million yen (for the first six months of the previous fiscal year, net cash used in
investing activities was 1,023 million yen). The main factors are purchase of property, plant and equipment of 1,922 million
yen, despite proceeds from collection of long-term loans receivable of 1,603 million yen.
(iii) Cash flows from financing activities
Net cash used in financing activities was 3,826 million yen (for the first six months of the previous fiscal year, net cash used
in financing activities was 3,880 million yen), mainly due to dividends paid of 3,787 million yen.
-6-
(3) Consolidated financial guidance
The Company reaffirms its full-year consolidated earnings forecast for the fiscal year ending March 31, 2027, as announced on
May 7, 2026.
For the six months ended September 30, 2026, in terms of net sales, EP/Ablation, Neurovascular, and Gastrointestinal performed
strongly relative to the forecast, offsetting somewhat weaker net sales of Cardiac Rhythm Management. Overall, net sales
progressed slightly ahead of our initial forecast. We anticipate that net sales will progress generally in line with our initial
guidance in the third quarter and beyond.
In terms of profit, each profit figure significantly exceeded the plan for the first half, mainly due to delays in the incurrence of
research and development expenses during the six months ended September 30, 2026. However, as these expenses are expected
to be largely incurred during the current fiscal year from the third quarter onward, we expect full-year profit figures to remain
generally in line with our initial guidance.
Should any revisions become necessary due to various factors, we will promptly disclose them.
-7-
- Interim Consolidated Financial Statements and Major Notes
(1) Interim consolidated balance sheets
(Millions of yen)
As of March 31, 2026
Assets
Current assets
Cash and deposits
Notes and accounts receivable - trade
Inventories
Other
Total current assets
Fixed assets
Property, plant and equipment
Buildings and structures, net
Other, net
Total property, plant and equipment
Intangible assets
Investments and other assets
Investment securities
Long-term loans receivable
Retirement benefit asset
Other
Allowance for doubtful accounts
Total investments and other assets
Total fixed assets
Total assets
Liabilities
Current liabilities
Notes and accounts payable - trade
Short-term borrowings
Accounts payable - other
Income taxes payable
Provision for bonuses
Provision for bonuses for directors
Other
Total current liabilities
Long-term liabilities
Provision for director’s stock based compensation
Other
Total long-term liabilities
Total liabilities
Net assets
Shareholders’ equity
Share capital
Capital surplus
Retained earnings
Treasury stock
Total shareholders’ equity
Accumulated other comprehensive income
Net unrealized holding gains or losses on securities
Foreign currency translation adjustment
Remeasurements of defined benefit plans
Total accumulated other comprehensive income
Share acquisition rights
Total net assets
Total liabilities and net assets
-8-
As of September 30, 2026
12,494
14,550
20,129
1,871
49,046
11,711
15,663
20,587
1,839
49,802
6,823
7,087
13,911
1,564
8,525
6,755
15,281
1,535
7,350
2,793
162
6,938
(1,557)
15,688
31,164
80,211
6,732
1,635
171
6,200
(1,354)
13,386
30,203
80,005
4,432
2,900
1,128
1,694
1,870
30
1,541
13,597
4,027
2,900
1,186
1,690
1,814
20
1,190
12,829
85
630
716
14,314
85
676
762
13,591
2,115
4,418
59,083
(1,208)
64,409
2,115
4,492
59,721
(1,262)
65,066
58
1,138
243
1,441
47
65,897
80,211
(125)
1,185
205
1,265
82
66,414
80,005
(2) Interim consolidated statements of income and interim consolidated statements of comprehensive income
(Interim consolidated statements of income)
(Millions of yen)
Six months ended
September 30, 2025
Net sales
Cost of sales
Gross profit
Selling, general and administrative expenses
Operating profit
Non-operating income
Interest income
Dividend income
Gain on valuation of investment securities
Reversal of allowance for doubtful accounts
Other
Total non-operating income
Non-operating expenses
Interest expenses
Loss on valuation of investment securities
Foreign exchange losses
Provision of allowance for doubtful accounts
Commission expenses
Other
Total non-operating expenses
Ordinary profit
Extraordinary income
Gain on sale of fixed assets
Gain on sale of investment securities
Total extraordinary income
Extraordinary losses
Loss on retirement of fixed assets
Total extraordinary losses
Profit before income taxes
Income taxes - current
Income taxes - deferred
Total income taxes
Net income
Net income attributable to owners of the parent
Six months ended
September 30, 2026
29,285
11,727
17,557
10,937
6,620
31,353
13,334
18,018
12,550
5,468
59
28
–
–
8
95
34
24
367
203
51
681
18
19
25
3
7
16
90
6,624
18
–
70
–
8
11
109
6,040
0
–
0
1
346
347
42
42
6,582
1,608
199
1,807
4,774
4,774
48
48
6,338
1,673
235
1,908
4,430
4,430
(Interim consolidated statements of comprehensive income)
(Millions of yen)
Six months ended
September 30, 2025
Net income
Other comprehensive income
Net unrealized holding gains or losses on securities
Foreign currency translation adjustment
Retirement benefits liability adjustment
Total other comprehensive income
Comprehensive income
Comprehensive income attributable to:
Owners of the parent
-9-
Six months ended
September 30, 2026
4,774
4,430
116
(121)
(102)
(107)
4,667
(184)
46
(38)
(176)
4,254
4,667
4,254
(3) Interim consolidated statements of cash flows
(Millions of yen)
Six months ended
September 30, 2025
Cash flows from operating activities
Profit before income taxes
Depreciation
Amortization of long-term prepaid expenses
Increase (decrease) in allowance for doubtful accounts
Increase (decrease) in provision for bonuses
Increase (decrease) in provision for bonuses for directors
Increase (decrease) in retirement benefit liability
Increase (decrease) in provision for directors’ stock based
compensation
Interest and dividend income
Interest expenses
Loss (gain) on sale and retirement of fixed assets
Loss (gain) on valuation of investment securities
Loss (gain) on sale of investment securities
Decrease (increase) in trade notes and accounts receivables
Decrease (increase) in inventories
Decrease (increase) in accounts receivable - other
Increase (decrease) in trade notes and accounts payables
Increase (decrease) in accrued consumption taxes
Increase (decrease) in accrued expenses
Other, net
Subtotal
Interest and dividends received
Interest paid
Income taxes paid
Net cash provided by (used in) operating activities
Cash flows from investing activities
Purchase of property, plant and equipment
Purchase of intangible assets
Proceeds from sale of fixed assets
Purchase of investment securities
Proceeds from sale of investment securities
Proceeds from distributions from investment partnerships
Short-term loan advances
Long-term loan advances
Proceeds from collection of long-term loans receivable
Other payments
Other proceeds
Net cash provided by (used in) investing activities
Cash flows from financing activities
Repayments of long-term borrowings
Repayments of lease liabilities
Dividends paid
Net cash provided by (used in) financing activities
Effect of exchange rate change on cash and cash equivalents
Net increase (decrease) in cash and cash equivalents
Cash and cash equivalents at beginning of period
Cash and cash equivalents at end of period
*1
Six months ended
September 30, 2026
6,582
814
159
(208)
(208)
(58)
(112)
6,338
811
153
(203)
(55)
(10)
(64)
(85)
(0)
(87)
18
42
19
–
(606)
(1,187)
(63)
97
(104)
(180)
188
5,019
37
(18)
(1,543)
3,495
(59)
18
47
(367)
(346)
(1,111)
(456)
235
(405)
(118)
(243)
113
4,277
692
(18)
(1,676)
3,274
(672)
(26)
0
(40)
–
–
–
(3)
5
(407)
119
(1,023)
(1,922)
(181)
1
(88)
786
385
(16)
(464)
1,603
(350)
4
(242)
(60)
(101)
(3,718)
(3,880)
24
(1,384)
11,014
9,630
–
(38)
(3,787)
(3,826)
11
(782)
12,494
*1 11,711
(4) Notes to interim consolidated financial statements
Going concern assumption
None
Significant changes in shareholders’ equity
None
Changes in scope of consolidation or application of equity method
JLL Med USA Inc. was newly established and has therefore been included in the scope of consolidation from the six months
ended September 30, 2026.
Interim consolidated statements of cash flows
*1 The relationship between the balance of cash and cash equivalents at the end of the periods and the amount of items listed in
the interim consolidated balance sheets is as follows:
(Millions of yen)
Six months ended
Six months ended
September 30, 2025
September 30, 2026
Cash and deposits
9,630
11,711
Cash and cash equivalents
9,630
11,711
Segment information, etc.
[Segment information]
Six months ended September 30, 2025 (from April 1, 2025 to September 30, 2025)
The Company and its consolidated subsidiaries are engaged in the manufacture and sale of medical devices, with principal
customers located in Japan. There are no reportable segments among the components of the Company and its consolidated
subsidiaries for which discrete financial information is available and whose operating results are regularly reviewed by the
Board of Directors to make decisions about management resources to be allocated and assess business performance.
Six months ended September 30, 2026 (from April 1, 2026 to September 30, 2026)
The Company and its consolidated subsidiaries are engaged in the manufacture and sale of medical devices, with principal
customers located in Japan. There are no reportable segments among the components of the Company and its consolidated
subsidiaries for which discrete financial information is available and whose operating results are regularly reviewed by the
Board of Directors to make decisions about management resources to be allocated and assess business performance.
Significant subsequent events
At the meeting of its Board of Directors held on September 29, 2026, the Company resolved to acquire U.S.-based Cross
Vascular, Inc. (“Cross Vascular”) through JLL Med USA Inc., a wholly owned subsidiary of the Company, and make Cross
Vascular an indirect wholly owned subsidiary of the Company. On October 1, 2026, the Company acquired the shares of Cross
Vascular, making it an indirect wholly owned subsidiary.
For details, please refer to “Japan Lifeline Announces Acquisition of U.S.-Based Cross Vascular and Change in Specified
Subsidiary Following Capital Increase” announced on September 29, 2026.
- Other
Status of production, orders received and sales
(i) Production
The production results for the six months ended September 30, 2025 and 2026, by product category, were as follows. There
were no significant changes.
Product Category
Six months ended
September 30, 2025
Cardiac Rhythm Management
(Millions of yen)
YoY %
increase/
(decrease)
Six months ended
September 30, 2026
5
7
39.2
EP/Ablation
3,132
3,725
18.9
Cardiovascular
836
846
1.3
Gastrointestinal
384
378
(1.4)
4,358
4,958
13.8
Total
Notes: 1. Figures are based on manufacturing cost.
- Neurovascular has been omitted because there was no production during either the six months ended September 30, 2025,
or the six months ended September 30, 2026.
(ii) Orders received
As the Group’s business model generally does not generate order backlogs, this information is omitted.
(iii) Sales results
Please refer to “1. Overview of Financial Performance (1) Operating results” on page 2 of the attached materials.